Senior Counsel Jennifer Hennessy was quoted in the Law360 article, “Amid Pandemic, Health Apps Face Privacy Law Patchwork,” which discussed how in a surging market thanks to the coronavirus pandemic, developers of mobile health apps are facing challenges on how to comply with a patchwork of state data security laws.
Much of the traditional health care space is covered by the rigorous data security requirements outlined by federal regulators in the Health Insurance Portability and Accountability Act, or HIPAA. But other companies, like private businesses building apps to screen employees for symptoms of COVID-19, may not be subject to HIPAA’s requirements despite handling sensitive health data.
Separately, the current FTC in May solicited input about whether it should change a decade-old, little-used rule requiring companies that are not covered by HIPAA but still handle health information to publicly report data breaches. The commission asked for advice on whether it should change its Health Breach Notification Rule in light of “legal, economic, and technological changes,” including “developments in health care products or services related to COVID-19.”
The FTC noted at the time that more companies may soon be covered by its rule as patients increasingly turn to technologies such as virtual assistants and mobile health apps that might not be subject to HIPAA. Those companies are instead struggling to navigate a slew of differing state laws addressing how health data should be protected and how to handle a potential data breach. “We think health care and HIPAA go together in this country, and that’s true most of the time, but not always,” Hennessy said.
Much of the traditional health care space is covered by the rigorous data security requirements outlined by federal regulators in the Health Insurance Portability and Accountability Act, or HIPAA. But other companies, like private businesses building apps to screen employees for symptoms of COVID-19, may not be subject to HIPAA’s requirements despite handling sensitive health data.
Separately, the current FTC in May solicited input about whether it should change a decade-old, little-used rule requiring companies that are not covered by HIPAA but still handle health information to publicly report data breaches. The commission asked for advice on whether it should change its Health Breach Notification Rule in light of “legal, economic, and technological changes,” including “developments in health care products or services related to COVID-19.”
The FTC noted at the time that more companies may soon be covered by its rule as patients increasingly turn to technologies such as virtual assistants and mobile health apps that might not be subject to HIPAA. Those companies are instead struggling to navigate a slew of differing state laws addressing how health data should be protected and how to handle a potential data breach. “We think health care and HIPAA go together in this country, and that’s true most of the time, but not always,” Hennessy said.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”